Identification and management of toxicities from immune checkpoint-blocking drugs

Benjamin A. Teply, Evan J. Lipson

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
JournalOncology (Williston Park, N.Y.)
Volume28
StatePublished - Nov 1 2014

Fingerprint

Pharmaceutical Preparations
Practice Guidelines
Antineoplastic Agents
Neoplasms
Therapeutics
ipilimumab
nivolumab
pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification and management of toxicities from immune checkpoint-blocking drugs. / Teply, Benjamin A.; Lipson, Evan J.

In: Oncology (Williston Park, N.Y.), Vol. 28, 01.11.2014, p. 30-38.

Research output: Contribution to journalReview article

@article{d382be59a0374e54bc4d28a54ae874d9,
title = "Identification and management of toxicities from immune checkpoint-blocking drugs",
abstract = "Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.",
author = "Teply, {Benjamin A.} and Lipson, {Evan J.}",
year = "2014",
month = "11",
day = "1",
language = "English (US)",
volume = "28",
pages = "30--38",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",

}

TY - JOUR

T1 - Identification and management of toxicities from immune checkpoint-blocking drugs

AU - Teply, Benjamin A.

AU - Lipson, Evan J.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.

AB - Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.

UR - http://www.scopus.com/inward/record.url?scp=84925379870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925379870&partnerID=8YFLogxK

M3 - Review article

C2 - 25384885

AN - SCOPUS:84925379870

VL - 28

SP - 30

EP - 38

JO - Oncology

JF - Oncology

SN - 0890-9091

ER -